OncoMatch/Clinical Trials/NCT06878274
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
Is NCT06878274 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for non small cell lung cancer.
This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery. The primary objective is to compare event-free survival (EFS) between patients receiving PORT targeting involved lymph node regions and those without PORT. Secondary and tertiary endpoints include overall survival, locoregional and distant control, toxicity, and quality of life. The phase II randomized trial will enroll 118 patients, stratifying by adjuvant immunotherapy use, with follow-up extending up to 5 years. Statistical analysis aims to detect a 15% improvement in 2-year EFS, with a total study duration of 7 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage III, T1-4N2-3
Baseline clinical or post-operative pathological stage III including specifically stage T1-4N2-3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: neoadjuvant chemotherapy — neoadjuvant
Completion of 2-4 cycles of neoadjuvant chemo-IO
Must have received: immunotherapy — neoadjuvant
Completion of 2-4 cycles of neoadjuvant chemo-IO
Must have received: surgical resection — post-complete (R0) surgical resection with mediastinal lymph node dissection
Status post-complete (R0) surgical resection with mediastinal lymph node dissection
Cannot have received: chest radiotherapy
Previous chest radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify